Multiple myeloma in association with second malignancy.

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Multiple myeloma (MM) is a hematologic malignancy.
• Understanding the incidence of second primary malignancies (SECMAL) in MM patients is crucial for comprehensive cancer care.
• Previous research has explored SECMAL in various cancers, but specific data for MM requires further investigation.

Purpose of the Study:

• To determine the frequency of second primary malignancies (SECMAL) in patients diagnosed with multiple myeloma (MM).
• To compare the incidence of SECMAL in MM patients with that in patients with solid tumors.

Main Methods:

• Retrospective analysis of medical records for 332 MM patients diagnosed between 1990-2010.
• Inclusion of a control group of 21,768 patients with solid tumors and SECMAL.
• Comparison of SECMAL incidence and timing between MM and solid tumor cohorts.

Main Results:

• SECMAL occurred in 4.52% of MM patients versus 5.09% in the solid tumor control group (p>0.05).
• In MM patients with SECMAL, the primary solid tumor diagnosis preceded MM in 66.67% of cases.
• Breast and gastric cancers were the most common SECMALs in MM patients (26.67% each).
• Median survival was significantly longer for MM patients with SECMAL (77.2 months) compared to the overall MM cohort (38.6 months; p<0.05).

Conclusions:

• The rate of SECMAL in multiple myeloma patients is comparable to that observed in other lymphoproliferative disorders and solid tumors.
• SECMAL is an infrequent event during the clinical course of multiple myeloma.
• The occurrence of SECMAL in MM is more likely in patients with longer survival.